Mariya Rozenblit

Mariya Rozenblit practices at Greenwich Hospital in Greenwich, Connecticut, part of Yale New Haven Health System.

Mariya Rozenblit's NPI, 1215315015, was assigned on May 12, 2015. Mariya Rozenblit graduated from Icahn School of Medicine at Mount Sinai in 2015. Mariya Rozenblit holds Connecticut license 68690.

Mariya Rozenblit's primary practice is Greenwich Hospital, at 5 Perryridge Rd, Greenwich, CT 06830 in Fairfield County. The practice phone is (203) 863-3000.

Mariya Rozenblit's primary practice is Greenwich Hospital in Greenwich, Connecticut, part of Yale New Haven Health System. Mariya Rozenblit is also affiliated with Yale New Haven Hospital. The medical group on file is Yale Health. Dmand AI also links Mariya Rozenblit to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Mariya Rozenblit practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Mariya Rozenblit's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Mariya Rozenblit is licensed in Connecticut.

CMS data shows 147 Medicare services from Mariya Rozenblit across 3 procedure codes in 2024, all of them office visits, for 87 Medicare patients. Medicare paid $13,761 for them.

CMS counts 87 Medicare patients who saw Mariya Rozenblit in 2024. The largest group is 75 to 84, with 40 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.06, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Mariya Rozenblit's median patient age at 71, with 97% women.

In 2024, Mariya Rozenblit wrote 354 Medicare Part D claims for 85 patients. 89% of them were for generic drugs. CMS names the drug for 291 of them, across 6 drugs with 11 or more claims each, at $539,779 in total drug cost. In 2023, CMS named 131 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Mariya Rozenblit for performance year 2024, reported as part of a group. Mariya Rozenblit accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Mariya Rozenblit as offering telehealth.

Dmand AI links 33 papers to Mariya Rozenblit, published from 2014 to 2025. 2014 was the busiest year, with 5. The most frequent topics are Breast Neoplasms, Biomarkers, Tumor and Germ-Line Mutation. Mariya Rozenblit has published most often in Breast Cancer Res. Mariya Rozenblit's most frequent co-authors are Lajos Pusztai, MD, James Krueger, MD, PhD and Julia Foldi, MD.

CMS Open Payments shows 7 general payments to Mariya Rozenblit from 4 drug and device companies from 2022 to 2025. Consulting fees make up the largest share, 94% of the total. AstraZeneca Pharmaceuticals LP paid the most, $5,020. It also lists 1 research payment totaling $763 in 2024.

Mariya Rozenblit graduated from Icahn School of Medicine at Mount Sinai in 2015.